President of a clinical-stage biotechnology company treating inflammatory diseases.• Overall responsibility for all finance, corporate development & strategy, legal & compliance, human resources, facilities, information technology, investor relations, and government & public relations functions.

Sanford Burnham Prebys is a preeminent, independent biomedical research institute dedicated to understanding human biology and disease and advancing scientific discoveries to profoundly impact human health. For over 50 years, SBP's research has produced breakthroughs in cancer, neuroscience, immunology and children’s diseases, and is anchored by SBP's NCI-designated cancer center and advanced drug discovery capabilities.

Advisory Board Member for a 2023 Time 100 Most Influential company focused on a functional application of advanced gene editing technology aimed at rebuilding the DNA of lost megafauna and other creatures (e.g., Wooly Mammoth) that had a measurably positive impact on our fragile ecosystems.

Chairman of the Board of Directors and Audit Committee Chairman for a clinical-stage biotechnology company developing new therapeutics focused on fundamentally changing the way inflammatory disease is treated by targeting NKT immune cells.

Board Member for a software company focused on personalized medicine and combination therapy in oncology. Technology guides oncologists in the selection of cancer drugs that are customized for individual patients based on their molecular tumor profile.

Chairman for a software company focused on automated, cloud-based, artificial intelligence applications to improve drug discovery and development.

During my tenure, helped Heron Therapeutics grow from an ~$300M to an ~$2.2B market cap, ~400 person commercial-stage biotechnology company (4 approved drugs: CINVANTI, ZYNRELEF, APONVIE & SUSTOL) focused on developing novel, patient-focused solutions that apply innovative science and technologies for patients suffering from cancer and pain. • Overall responsibility for all finance, corporate development & strategy, legal & compliance, human resources, facilities, information technology, investor relations, and government & public relations functions. Partner with Chief Commercial Officer as a member of Commercial Leadership Team.

Chairman for a software company that addresses the “big data” challenges associated with genomic data that is generated by today’s next generation sequencing platforms.

Member of the Board of Directors for a clinical-stage biotechnology company developing new therapeutics that target debilitating allergic and inflammatory diseases in orphan or focused patient populations.

Member of the Board of Directors for a hardware company that developed the DRAGEN™ Bio-IT Processor, the world’s first next-generation sequencing bioinformatics application-specific integrated circuit (ASIC). This chip is able to analyze the large amounts of data generated by next-generation sequencing rapidly and cost effectively, without compromising accuracy, and overcoming a key bottleneck in the DNA sequencing workflow. The Scientist named the DRAGEN ™ Bio-IT Processor as the No. 1 product innovation in 2014.

During my tenure, helped grow Regulus Therapeutics Inc. from an ~$300M to an ~$1.2B market cap, ~100 person clinical-stage biotechnology company leading the discovery and development of innovative medicines and diagnostics targeting microRNAs focused on oncology, fibrosis, hepatitis C and metabolic diseases.• Overall responsibility for all corporate development & strategy, finance & accounting, strategic alliances, legal & compliance, corporate secretary, facilities, and information technology functions.

Was a $4B revenue global biotechnology company with 50k+ products, 5k+ patents and licenses, a presence in 180 countries,10k+ employees and a worldwide leader in biotech acquisitions. Major recognition included naming by The Deal in 2011 as 1 of 5 “Most Admired Corporate Dealmakers in the Healthcare Sector,” and by Fast Company in 2012 as the #1 “Most Innovative Biotech” and #9 of the “50 Most Innovative Companies.” • 1 of 9 corporate officers appointed by the Board of Directors. • Led 50+ domestic and worldwide acquisitions, divestitures, equity investments (including joint ventures and partnerships), and debt transactions, totaling $30B+, including leading the $15.8B sale of Life Technologies to Thermo Fisher Scientific in 2013.

Associate in Corporate Group.

Associate in Corporate Group.

Associate in Corporate Group.

Former technology focused boutique investment bank. Among the most active during the dotcom boom, underwriting 70+ initial public offerings (IPOs). • Served in a traditionally post-MBA position during the dotcom boom. Analyzed and advised on M&A deals and capital market deals for investment banking clients.